These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 7689227)

  • 1. Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein.
    Rodman TC; To SE; Hashish H; Manchester K
    Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7719-23. PubMed ID: 7689227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human immunodeficiency virus (HIV) Tat-reactive antibodies present in normal HIV-negative sera and depleted in HIV-positive sera. Identification of the epitope.
    Rodman TC; Pruslin FH; To SE; Winston R
    J Exp Med; 1992 May; 175(5):1247-53. PubMed ID: 1373758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating natural IgM antibodies and their corresponding human cord blood cell-derived Mabs specifically combat the Tat protein of HIV.
    Rodman TC; Lutton JD; Jiang S; Al-Kouatly HB; Winston R
    Exp Hematol; 2001 Aug; 29(8):1004-9. PubMed ID: 11495706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant.
    Borsutzky S; Fiorelli V; Ebensen T; Tripiciano A; Rharbaoui F; Scoglio A; Link C; Nappi F; Morr M; Buttó S; Cafaro A; Mühlradt PF; Ensoli B; Guzmán CA
    Eur J Immunol; 2003 Jun; 33(6):1548-56. PubMed ID: 12778472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The human uniqueness of HIV: innate immunity and the viral Tat protein.
    Rodman TC; Sullivan JJ; Bai X; Winston R
    Hum Immunol; 1999 Aug; 60(8):631-9. PubMed ID: 10439309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tat-neutralizing antibodies in vaccinated macaques.
    Tikhonov I; Ruckwardt TJ; Hatfield GS; Pauza CD
    J Virol; 2003 Mar; 77(5):3157-66. PubMed ID: 12584340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of human immunodeficiency virus type 1 replication in vitro in acutely and persistently infected human CD4+ mononuclear cells expressing murine and humanized anti-human immunodeficiency virus type 1 Tat single-chain variable fragment intrabodies.
    Mhashilkar AM; LaVecchio J; Eberhardt B; Porter-Brooks J; Boisot S; Dove JH; Pumphrey C; Li X; Weissmahr RN; Ring DB; Ramstedt U; Marasco WA
    Hum Gene Ther; 1999 Jun; 10(9):1453-67. PubMed ID: 10395371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B-cell epitopes in HIV-1 Tat and Rev proteins colocalize with T-cell epitopes and with functional domains.
    Tähtinen M; Ranki A; Valle SL; Ovod V; Krohn K
    Biomed Pharmacother; 1997; 51(10):480-7. PubMed ID: 9863510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationships between the presence of anti-Tat antibody, DNA and RNA viral load.
    Re MC; Gibellini D; Furlini G; Vignoli M; Vitone F; Bon I; La Placa M
    New Microbiol; 2001 Jul; 24(3):207-15. PubMed ID: 11497076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequence variation within the dominant amino terminus epitope affects antibody binding and neutralization of human immunodeficiency virus type 1 Tat protein.
    Ruckwardt TJ; Tikhonov I; Berg S; Hatfield GS; Chandra A; Chandra P; Gilliam B; Redfield RR; Gallo RC; Pauza CD
    J Virol; 2004 Dec; 78(23):13190-6. PubMed ID: 15542671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies against a multiple-peptide conjugate comprising chemically modified human immunodeficiency virus type-1 functional Tat peptides inhibit infection.
    Devadas K; Boykins RA; Hewlett IK; Wood OL; Clouse KA; Yamada KM; Dhawan S
    Peptides; 2007 Mar; 28(3):496-504. PubMed ID: 17188401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Important B-cell epitopes for neutralization of human immunodeficiency virus type 1 Tat in serum samples of humans and different animal species immunized with Tat protein or peptides.
    Moreau E; Belliard G; Partidos CD; Pradezinsky F; Le Buanec H; Muller S; Desgranges C
    J Gen Virol; 2004 Oct; 85(Pt 10):2893-2901. PubMed ID: 15448351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection.
    Richardson MW; Mirchandani J; Duong J; Grimaldo S; Kocieda V; Hendel H; Khalili K; Zagury JF; Rappaport J
    Biomed Pharmacother; 2003 Jan; 57(1):4-14. PubMed ID: 12642031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 Tat-specific IgG antibodies in high-responders target a B-cell epitope in the cysteine-rich domain and block extracellular Tat efficiently.
    Kashi VP; Jacob RA; Paul S; Nayak K; Satish B; Swaminathan S; Satish KS; Ranga U
    Vaccine; 2009 Nov; 27(48):6739-47. PubMed ID: 19744585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation and characterization of neutralizing human monoclonal antibodies against human immunodeficiency virus type 1 Tat antigen.
    Moreau E; Hoebeke J; Zagury D; Muller S; Desgranges C
    J Virol; 2004 Apr; 78(7):3792-6. PubMed ID: 15016898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA immunization with HIV-1 tat mutated in the trans activation domain induces humoral and cellular immune responses against wild-type Tat.
    Caselli E; Betti M; Grossi MP; Balboni PG; Rossi C; Boarini C; Cafaro A; Barbanti-Brodano G; Ensoli B; Caputo A
    J Immunol; 1999 May; 162(9):5631-8. PubMed ID: 10228047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epitopes of the HIV-1-negative factor (nef) reactive with murine monoclonal antibodies and human HIV-1-positive sera.
    Schneider T; Harthus HP; Hildebrandt P; Niedrig M; Bröker M; Weigelt W; Beck A; Pauli G
    AIDS Res Hum Retroviruses; 1991 Jan; 7(1):37-44. PubMed ID: 1707640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans.
    Buttò S; Fiorelli V; Tripiciano A; Ruiz-Alvarez MJ; Scoglio A; Ensoli F; Ciccozzi M; Collacchi B; Sabbatucci M; Cafaro A; Guzmán CA; Borsetti A; Caputo A; Vardas E; Colvin M; Lukwiya M; Rezza G; Ensoli B;
    J Infect Dis; 2003 Oct; 188(8):1171-80. PubMed ID: 14551888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients.
    Re MC; Vignoli M; Furlini G; Gibellini D; Colangeli V; Vitone F; La Placa M
    J Clin Virol; 2001 Apr; 21(1):81-9. PubMed ID: 11255101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two B cell epitopes of HIV-1 Tat protein have limited antigenic polymorphism in geographically diverse HIV-1 strains.
    Goldstein G; Tribbick G; Manson K
    Vaccine; 2001 Feb; 19(13-14):1738-46. PubMed ID: 11166899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.